Hemodynamic, renal, and hormonal responses to alpha-human atrial natriuretic peptide in patients with congestive heart failure
Related Experiment Videos
Insights
Synthetic alpha-human atrial natriuretic peptide (alpha-hANP) administration in heart failure patients lowered blood pressure and vascular resistance without reflex tachycardia. It also improved cardiac output and natriuresis, while suppressing key hormones.
Area of Science:
- Cardiology
- Nephrology
- Endocrinology
Background:
- Congestive heart failure (CHF) is characterized by complex hemodynamic, renal, and hormonal dysregulations.
- Atrial natriuretic peptide (ANP) plays a crucial role in cardiovascular and renal homeostasis.
Purpose of the Study:
- To investigate the acute hemodynamic, renal, and hormonal effects of synthetic alpha-human atrial natriuretic peptide (alpha-hANP) in patients with CHF.
Main Methods:
- Eight patients with CHF received an intravenous bolus injection of 50 micrograms of synthetic alpha-hANP.
- Hemodynamic parameters, renal function markers, and plasma hormone levels were monitored.
Main Results:
- A significant reduction in mean blood pressure and systemic vascular resistance was observed, sustained for 90 minutes without reflex tachycardia.
- Cardiac index and stroke volume index increased significantly at 90 minutes.
- Urine volume, sodium excretion, and creatinine clearance increased, while plasma renin activity, aldosterone, and norepinephrine were suppressed.
Conclusions:
- Intravenous bolus injection of alpha-hANP demonstrates moderate hypotensive, vasorelaxant, and natriuretic effects in patients with congestive heart failure.
- These effects are accompanied by favorable changes in renal function and suppression of the renin-angiotensin-aldosterone system and sympathetic nervous system.
Abstract:
Hemodynamic, renal, and hormonal effects of intravenous bolus injection of 50 micrograms synthetic alpha-human atrial natriuretic peptide (alpha-hANP) were studied in eight patients with congestive heart failure. alpha-hANP caused significant reductions in mean blood pressure and systemic vascular resistance. These responses were sustained up to 90 minutes and not accompanied by reflex tachycardia. Cardiac index and stroke volume index increased significantly at 90 minutes and pulmonary capillary wedge pressure, pulmonary arterial pressure, and mean right atrial pressure remained unchanged. Urine volume, urinary sodium excretion, creatinine clearance, and fractional excretion of sodium increased significantly, but fractional excretion of potassium and phosphate did not change. Elevated plasma renin activity, plasma aldosterone, and norepinephrine were suppressed after the injection of alpha-hANP. The bolus injection of this peptide has moderately hypotensive, vasorelaxant, and natriuretic effects in patients with congestive heart failure.